Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9750)
All Articles published online
|
Publishing Process of This Article
|
Jun 28, 2018 (publication date) through Nov 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Guarino M, Sessa A, Cossiga V, Morando F, Caporaso N, Morisco F, On behalf of the Special Interest Group on “Hepatocellular carcinoma and new anti-HCV therapies” of the Italian Association for the Study of the Liver. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows. World J Gastroenterol 2018; 24(24): 2582-2595 [PMID: 29962815 DOI: 10.3748/wjg.v24.i24.2582] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v24/i24/2582.htm |
| Number | Citing Articles |
| 1 |
Myung‐Won You, Kyung Won Kim, Jae‐Jun Shim, Junhee Pyo. Impact of liver‐stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct‐acting antivirals: A systematic review and time‐to‐event meta‐analysis. Journal of Gastroenterology and Hepatology 2021; 36(3): 601 doi: 10.1111/jgh.15243
|
| 2 |
Wei-Chen Lin, Yang-Sheng Lin, Chen-Wang Chang, Ching-Wei Chang, Tsang-En Wang, Horng-Yuan Wang, Ming-Jen Chen, Chen-Hua Liu. Impact of direct-acting antiviral therapy for hepatitis C–related hepatocellular carcinoma. PLOS ONE 2020; 15(5): e0233212 doi: 10.1371/journal.pone.0233212
|
| 3 |
Kartikeya Khanna, Eleanor Barnes, Jennifer Benselin, Emma Culver, William Irving, Hamish Innes, Michael Pavlides, DeLIVER Consortium. Prospective cohort for early detection of liver cancer (Pearl): a study protocol. BMJ Open 2024; 14(10): e085541 doi: 10.1136/bmjopen-2024-085541
|
| 4 |
Walaa Abdelhamed, Mohamed El‐Kassas. Hepatocellular carcinoma and hepatitis C virus treatments: The bold and the beautiful. Journal of Viral Hepatitis 2023; 30(2): 148 doi: 10.1111/jvh.13778
|
| 5 |
Luca Rinaldi, Maria Guarino, Alessandro Perrella, Pia Clara Pafundi, Giovanna Valente, Luca Fontanella, Riccardo Nevola, Barbara Guerrera, Natalina Iuliano, Michele Imparato, Alessio Trabucco, Ferdinando Carlo Sasso, Filomena Morisco, Antonio Ascione, Guido Piai, Luigi Elio Adinolfi. Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience. Digestive Diseases and Sciences 2019; 64(10): 3013 doi: 10.1007/s10620-019-05604-8
|
| 6 |
Martynas Ridziauskas, Birutė Zablockienė, Ligita Jančorienė, Artūras Samuilis, Rolandas Zablockis, Aušrinė Jackevičiūtė. Assessment of Liver Stiffness Regression and Hepatocellular Carcinoma Risk in Chronic Hepatitis C Patients after Treatment with Direct-Acting Antiviral Drugs. Medicina 2021; 57(3): 210 doi: 10.3390/medicina57030210
|
| 7 |
Altaira D. Dearborn, Joseph Marcotrigiano. Hepatitis C Virus Structure: Defined by What It Is Not. Cold Spring Harbor Perspectives in Medicine 2020; 10(1): a036822 doi: 10.1101/cshperspect.a036822
|
| 8 |
Chiara Rocha, Joseph Di Norcia, Parissa Tabrizian, Chiara Di Renzo, Salvatore Amodeo, Yuki Bekki, Mohammed Z. Akhtar, Marcelo E. Facciuto, Thomas D. Schiano, Sander Florman, Myron Schwartz. Improved outcomes of liver resection for hepatitis C-related hepatocellular carcinoma after the introduction of direct-acting antiviral therapy. HPB 2024; 26(8): 1007 doi: 10.1016/j.hpb.2024.04.014
|
| 9 |
Johnathan D. Guest, Brian G. Pierce. Structure-Based and Rational Design of a Hepatitis C Virus Vaccine. Viruses 2021; 13(5): 837 doi: 10.3390/v13050837
|
| 10 |
Zobair Younossi, Georgios Papatheodoridis, Patrice Cacoub, Francesco Negro, Heiner Wedemeyer, Linda Henry, Angelos Hatzakis. The comprehensive outcomes of hepatitis C virus infection: A multi‐faceted chronic disease. Journal of Viral Hepatitis 2018; 25(S3): 6 doi: 10.1111/jvh.13005
|
| 11 |
Salmann Ali, Ammara Naveed, Irshad Hussain, Javaria Qazi. Diagnosis and monitoring of hepatocellular carcinoma in Hepatitis C virus patients using attenuated total reflection Fourier transform infrared spectroscopy. Photodiagnosis and Photodynamic Therapy 2023; 43: 103677 doi: 10.1016/j.pdpdt.2023.103677
|
| 12 |
Xi Zhong, Tianpei Guan, Danrui Tang, Jiansheng Li, Bingui Lu, Shuzhong Cui, Hongsheng Tang. Differentiation of small (≤ 3 cm) hepatocellular carcinomas from benign nodules in cirrhotic liver: the added additive value of MRI-based radiomics analysis to LI-RADS version 2018 algorithm. BMC Gastroenterology 2021; 21(1) doi: 10.1186/s12876-021-01710-y
|
| 13 |
Ahmad M. Zidan, Eman A. Saad, Nasser E. Ibrahim, Medhat H. Hashem, Amal Mahmoud, Alaa A. Hemeida. Host pharmacogenetic factors that may affect liver neoplasm incidence upon using direct-acting antivirals for treating hepatitis C infection. Heliyon 2021; 7(5): e06908 doi: 10.1016/j.heliyon.2021.e06908
|
| 14 |
Ahmed Kamal, Ahmed Elsheaita, Mahmoud Abdelnabi. Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate. World Journal of Clinical Cases 2022; 10(6): 1764-1774 doi: 10.12998/wjcc.v10.i6.1764
|
| 15 |
Loraine Kay D. Cabral, Luca Grisetti, Muhammad Yogi Pratama, Claudio Tiribelli, Devis Pascut. Biomarkers for the Detection and Management of Hepatocellular Carcinoma in Patients Treated with Direct-Acting Antivirals. Cancers 2022; 14(11): 2700 doi: 10.3390/cancers14112700
|
| 16 |
I. Santana-Salgado, A. Bautista-Santos, R. Moreno-Alcántar. Factores de riesgo para desarrollar carcinoma hepatocelular en pacientes tratados con antivirales de acción directa. Revista de Gastroenterología de México 2022; 87(4): 455 doi: 10.1016/j.rgmx.2021.03.007
|
| 17 |
Amy Lee, Fa-Chyi Lee. Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check. Frontiers of Medicine 2020; 14(3): 273 doi: 10.1007/s11684-019-0728-2
|
| 18 |
Wafaa M. Rashed, Mohamed Ahmed Mohamed Kandeil, Mohamed O. Mahmoud, Sameera Ezzat. Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview. Journal of the Egyptian National Cancer Institute 2020; 32(1) doi: 10.1186/s43046-020-0016-x
|
| 19 |
Itaru Ozeki, Tomoaki Nakajima, Hirokazu Suii, Ryoji Tatsumi, Masakatsu Yamaguchi, Tomohiro Arakawa, Yasuaki Kuwata. Predictors of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting antiviral treatment: relationship with serum zinc. Journal of Clinical Biochemistry and Nutrition 2020; 66(3): 245 doi: 10.3164/jcbn.19-98
|
| 20 |
Akifumi Kuwano, Masayoshi Yada, Shigehiro Nagasawa, Kosuke Tanaka, Yusuke Morita, Akihide Masumoto, Kenta Motomura. Serum α‐fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct‐acting antiviral treatment. Journal of Viral Hepatitis 2022; 29(1): 35 doi: 10.1111/jvh.13625
|
| 21 |
Valentina Telatin, Francesco Nicoli, Chiara Frasson, Nicola Menegotto, Francesco Barbaro, Eleonora Castelli, Elke Erne, Giorgio Palù, Antonella Caputo. In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral Treatment. Frontiers in Cellular and Infection Microbiology 2019; 9 doi: 10.3389/fcimb.2019.00190
|
| 22 |
Giacomo Emanuele Maria Rizzo, Giuseppe Cabibbo, Antonio Craxì. Hepatitis B Virus-Associated Hepatocellular Carcinoma. Viruses 2022; 14(5): 986 doi: 10.3390/v14050986
|
| 23 |
Kung-Hao Liang, Ming-Wei Lai, Yang-Hsiang Lin, Yu-De Chu, Chih-Lang Lin, Wey-Ran Lin, Ya-Hui Huang, Tong-Hung Wang, Rong-Nan Chien, Tsung-Hui Hu, Chau-Ting Yeh. Plasma interleukin-17 and alpha-fetoprotein combination effectively predicts imminent hepatocellular carcinoma occurrence in liver cirrhotic patients. BMC Gastroenterology 2021; 21(1) doi: 10.1186/s12876-021-01761-1
|
| 24 |
Mohamed Omran, Manar Fouda, Abdelwahab Osama Abdelwahab, Mohamed Mahmoud Nabeel, Ashraf Omar Abdelaziz, Dalia Omran, Hend Ibrahim Shousha. P53 is a risk factor of de-novo hepatitis C-related hepatocellular carcinoma treated with direct-acting antivirals: a case-control study. European Journal of Gastroenterology & Hepatology 2022; 34(2): 220 doi: 10.1097/MEG.0000000000001962
|
| 25 |
José Ríos, Víctor Sapena, Zoe Mariño, Jordi Bruix, Xavier Forns, Rosa Morros, María Reig, Ferran Torres, Caridad Pontes. Incidence of Liver and Non-liver Cancers After Hepatitis C Virus Eradication: A Population-Based Cohort Study. Drugs - Real World Outcomes 2024; 11(3): 389 doi: 10.1007/s40801-024-00437-y
|
| 26 |
Faten Farouk, Ibrahim M. Ibrahim, Salma Sherif, Heba Gamal Abdelhamed, Marwa Sharaky, Ahmed A. Al‐Karmalawy. Investigating the effect of polymerase inhibitors on cellular proliferation: Computational studies, cytotoxicity, CDK1 inhibitory potential, and LC‐MS/MS cancer cell entrapment assays. Chemical Biology & Drug Design 2024; 103(3) doi: 10.1111/cbdd.14500
|
| 27 |
Thong Duy Vo, Van Thi Thu Bui, Huong Tu Lam, Quynh Thi Huong Bui. High efficacy and safety of direct‐acting antivirals for the treatment of chronic hepatitis C: A cohort study conducted in Vietnam. Pharmacology Research & Perspectives 2024; 12(5) doi: 10.1002/prp2.70007
|
| 28 |
Cátia Dias, Filipa Duarte-Ribeiro, Sara Pipa, Ana Rita Barbosa, Margarida Mota, Fernando Rosas Vieira. Hepatocellular carcinoma after direct-acting antiviral therapy for chronic HCV infection: Is it a real risk?. IDCases 2018; 14: e00450 doi: 10.1016/j.idcr.2018.e00450
|
| 29 |
Arthi Venkatesan, Febin Prabhu Dass J.. Review on chemogenomic approaches towards hepatitis C viral targets. Journal of Cellular Biochemistry 2019; 120(8): 12167 doi: 10.1002/jcb.28581
|
| 30 |
Ashraf Omar, Ahmed Kaseb, Tamer Elbaz, Mohamed El-Kassas, Amr El Fouly, Abdel Fatah Hanno, Ahmed El Dorry, Ahmed Hosni, Amr Helmy, Amr S Saad, Ashwaq Alolayan, Basem Eysa, Emad Hamada, Hamdy Azim, Hany Khattab, Hesham Elghazaly, Hesham Tawfik, Hisham Ayoub, Hussein Khaled, Ibtessam Saadeldin, Imam Waked, Eman Barakat, Mahmoud El Meteini, Mohamed Hamed Shaaban, Mohamed EzzElarab, Mohamed Fathy, Mohamed Shaker, Mohamed Sobhi, Mohamed Shaker, Mohamed ElGharib, Mohammed Abdullah, Mohesn Mokhtar, Mostafa Elshazli, Omar Heikal, Osama Hetta, Reda ElWakil, Sameh Abdel Wahab, Samir Eid, Yousri Rostom. Egyptian Society of Liver Cancer Recommendation Guidelines for the Management of Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma 2023; : 1547 doi: 10.2147/JHC.S404424
|
| 31 |
Javeria Khalid, Mohammad Umar, Tofeeq Ur-Rehman, Mashhood Ali, Gul Majid Khan. Tumor aggression among hepatitis-C related hepatocellular carcinoma patients: an observational study regarding the impact of anti-HCV therapy. Infectious Agents and Cancer 2020; 15(1) doi: 10.1186/s13027-020-00300-z
|
| 32 |
I. Santana-Salgado, A. Bautista-Santos, R. Moreno-Alcántar. Risk factors for developing hepatocellular carcinoma in patients treated with direct-acting antivirals. Revista de Gastroenterología de México (English Edition) 2022; 87(4): 455 doi: 10.1016/j.rgmxen.2021.09.005
|
| 33 |
Mohamad Saeed Marie, Hend Ibrahim Shousha, Wael Abdelrazek, Mohamad Hassany, Hosam Dabees, Reem Abdelghafour, Walaa mosaad Aboganob, Mohamed Said. Prediction of hepatic decompensation and hepatocellular carcinoma after direct-acting antiviral therapy in patients with hepatitis C-related liver cirrhosis: a cohort study. Egyptian Liver Journal 2023; 13(1) doi: 10.1186/s43066-023-00247-x
|
| 34 |
Xinhua Zou, Wenzhe Fan, Miao Xue, Jiaping Li. Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression. Cancer Management and Research 2021; : 4013 doi: 10.2147/CMAR.S304591
|
| 35 |
Maria Guarino, Giovan Giuseppe Di Costanzo, Dario Bruzzese, Anna Sessa, Marco Guarracino, Luca Rinaldi, Andrea Aglitti, Angelo Salomone Megna, Federica Morando, Nicola Coppola, Nicola Caporaso, Filomena Morisco. Incidence of HCC recurrence after DAA treatment for HCV in a multicentre Italian cohort study. Liver Cancer International 2020; 1(1): 12 doi: 10.1002/lci2.13
|
| 36 |
C Wendy Spearman, Geoffrey M Dusheiko, Margaret Hellard, Mark Sonderup. Hepatitis C. The Lancet 2019; 394(10207): 1451 doi: 10.1016/S0140-6736(19)32320-7
|
| 37 |
Nashwa El‐Khazragy, Amal Ali Elshimy, Safaa Shawky Hassan, Mohamed Hafez Shaaban, Ahmed Hamed Bayoumi, Hekmat M. El Magdoub, Sherief Ghozy, Ahmed Gaballah, Marwa M. Aboelhussein, Hoda H. Abou Gabal, Azzah M. Bannunah, Azza EL‐Sayed Mansy. lnc‐HOTAIR predicts hepatocellular carcinoma in chronic hepatitis C genotype 4 following direct‐acting antivirals therapy. Molecular Carcinogenesis 2020; 59(12): 1382 doi: 10.1002/mc.23263
|
| 38 |
Reina Sasaki, Tatsuo Kanda, Naoya Kato, Osamu Yokosuka, Mitsuhiko Moriyama. Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response. World Journal of Hepatology 2018; 10(12): 898-906 doi: 10.4254/wjh.v10.i12.898
|
| 39 |
Eric Lawitz, Fred Poordad, Julio A. Gutierrez, Maria Beumont, Greet Beets, Ann Vandevoorde, Pieter Van Remoortere, Donghan Luo, Leen Vijgen, Veerle Van Eygen, Mohamed Gamil. Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study. Health Science Reports 2020; 3(2) doi: 10.1002/hsr2.145
|
| 40 |
Victor Kupriyanov, Lyudmila Nikolaeva, Alexander Grishechkin, Evgeny Samokhvalov, Anna Dedova, Anna Zykova, Nikolai Ravin. Dendritic cells derived from induced pluripotent stem cells and stimulated by antigens of hepatitis C virus efficiently activate T-lymphocytes. Journal of Biosciences 2024; 49(4) doi: 10.1007/s12038-024-00469-0
|
| 41 |
Po-Yuan Ke. The Multifaceted Roles of Autophagy in Flavivirus-Host Interactions. International Journal of Molecular Sciences 2018; 19(12): 3940 doi: 10.3390/ijms19123940
|
| 42 |
Gamal Shiha, Nasser Mousa, Reham Soliman, Nabiel NNH Mikhail, Mohamed Adel Elbasiony, Mahmoud Khattab. Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study. Journal of Viral Hepatitis 2020; 27(7): 671 doi: 10.1111/jvh.13276
|
| 43 |
Matteo Renzulli, Nicolò Brandi, Giulia Argalia, Stefano Brocchi, Andrea Farolfi, Stefano Fanti, Rita Golfieri. Morphological, dynamic and functional characteristics of liver pseudolesions and benign lesions. La radiologia medica 2022; 127(2): 129 doi: 10.1007/s11547-022-01449-w
|
| 44 |
Stefania Brozzetti, Marsia Tancredi, Simone Bini, Chiara De Lucia, Jessica Antimi, Chiara D’Alterio, Giuseppe Maria De Sanctis, Caterina Furlan, Vittoria Carolina Malpassuti, Pierleone Lucatelli, Michele Di Martino, Mario Bezzi, Antonio Ciardi, Rosa Maria Pascale. HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly. Cancers 2021; 13(12): 3025 doi: 10.3390/cancers13123025
|
| 45 |
Shahab Mahmoudvand, Somayeh Shokri, Reza Taherkhani, Fatemeh Farshadpour. Hepatitis C virus core protein modulates several signaling pathways involved in hepatocellular carcinoma. World Journal of Gastroenterology 2019; 25(1): 42-58 doi: 10.3748/wjg.v25.i1.42
|
| 46 |
Shen Li, Antonio Saviano, Derek J. Erstad, Yujin Hoshida, Bryan C. Fuchs, Thomas Baumert, Kenneth K. Tanabe. Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. Journal of Clinical Medicine 2020; 9(12): 3817 doi: 10.3390/jcm9123817
|
| 47 |
Mohammad Enamul Hoque Kayesh, Michinori Kohara, Kyoko Tsukiyama-Kohara. Epidemiology and Risk Factors for Acute Viral Hepatitis in Bangladesh: An Overview. Microorganisms 2022; 10(11): 2266 doi: 10.3390/microorganisms10112266
|
| 48 |
2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. Journal of Clinical and Experimental Hepatology 2020; 10(1): 43 doi: 10.1016/j.jceh.2019.09.007
|
| 49 |
Jelena Djokic Kovac, Aleksandar Ivanovic, Tamara Milovanovic, Marjan Micev, Francesco Alessandrino, Richard M. Gore. An overview of hepatocellular carcinoma with atypical enhancement pattern: spectrum of magnetic resonance imaging findings with pathologic correlation. Radiology and Oncology 2021; 55(2): 130 doi: 10.2478/raon-2021-0004
|